A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

About the Study

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer. Participants will be placed into study groups based on their tumor.

What the Study Entails

The study involves 6 groups:

Group 1:

Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and bevacizumab (Avastin) intravenously every two weeks of the 28-day cycle. 

Group 2:

Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Ipatasertib orally once daily for 21 days of the 28-day cycle.

Group 3:

Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Talazoparib (or Talzenna) orally once daily for every day of the 28-day cycle.

Group 4:

Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Trastuzumab emtansine (or Kadcyla) intravenously on Day 1 of each 21-day cycle.

Group 5:

Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Tiragolumab intravenously on Day 1 of each 28-day cycle.

Group 6:

Participants will receive Inavolisib and Lentrozole (or Femara) orally once daily for every day of the 28-day cycle.

Study Sites

California

• Duarte
  City of Hope Comprehensive Cancer Center
  Contact: Daphne Stewart
• San Francisco
  UCSF Helen Diller Family Comprehensive Center
  Contact: Edwin Alvarez

District of Columbia

• District of Columbia
  Medstar Georgetown Cancer Institute
  Contact: Ebony Hoskins

Florida

• Miami Beach
  Mount Sinai Comprehensive Cancer Center
  Contact: Brian Slomovitz

Illinois

• Chicago
  University of Chicago
  Contact: John Moroney

Kansas

• Westwood
  University of Kansas Cancer Center
  Contact: Andrea Jewell, MD

Massachusetts

• Boston
  Dana Farber Cancer Institute
  Contact: Joyce Liu

Minnesota

• Minneapolis
  University of Minnesota
  Contact: Britt Erickson

Missouri

• Saint Louis
  Washington University School of Medicine Siteman Cancer Center
  Contact: Premal Thaker

Nebraska

• Omaha
  Nebraska Methodist Hospital
  Contact: Brent Tierney

New Jersey

• Englewood
  Englewood Health
  Contact: Nimesh Nagarsheth
• Morristown
  Atlantic Health Systems/Morristown Medical Center
  Contact: Nana Tchabo

New York

• New York
• Weill Cornell Medicine
  Contact: Evelyn Cantillo

North Carolina

• Durham
  Duke University Cancer Center
  Contact: Angeles Alvarez Secord

Oklahoma

• Oklahoma City
  University of Oklahoma Health Stephenson Cancer Center
  Contact: Debra Richardson, MD

Oregon

• Portland
  Providence Portland Cancer Institute
  Contact: Christopher Darus

Pennsylvania

• Pittsburgh
  University of Pittsburgh Medical Center
  Contact: Alexander B. Olawaiye

Rhode Island

• Providence
  Lifespan - Rhode Island Hospital
  Contact: Don Dizon, MD

Women 18 years or older who:

• have a life expectancy of more than 12 weeks
• have recovered from effects of recent chemotherapy, radiation, or surgery
• have a tumor sample 
• have recurrent endometrial cancer which has recurred after at least one but no more than two prior forms of therapy

Patients with:

• other invasive cancers within the last five years
• an active or history of autoimmune disease or immune deficiency
• active tuberculosis
• have significant heart disease
• have received a live vaccine in the last four weeks
• have had a severe infection within the last four weeks
• have had prior bone marrow transplant or antibiotic medication through the vein within the past four weeks
• More exclusion criteria found on clinicaltrials.gov